K. Tandjung

发表

Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial

M. Stoel, C. von Birgelen, G. Linssen, 2017, JAMA cardiology.

Comparison of frequency of periprocedural myocardial infarction in patients with and without diabetes mellitus to those with previously unknown but elevated glycated hemoglobin levels (from the TWENTE Trial).

J. W. Louwerenburg, M. Stoel, R. Stolk, 2012, The American journal of cardiology.

Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and non-enrolled TWENTE registry.

M. Stoel, C. von Birgelen, G. Linssen, 2014, International journal of cardiology.

Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2018, JACC: Cardiovascular Interventions.

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial.

M. Stoel, C. von Birgelen, G. Linssen, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Complex patients treated with zotarolimus‐eluting resolute and everolimus‐eluting xience V stents in the randomized TWENTE trial: Comparison of 2‐year clinical outcome

J. W. Louwerenburg, M. Stoel, F. H. Man, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial.

C. von Birgelen, G. Linssen, F. de Man, 2015, American heart journal.

Scanning electron microscopic assessment of coating irregularities and their precursors in unexpanded durable polymer‐based drug‐eluting stents

D. Grijpma, C. von Birgelen, A. V. van Apeldoorn, 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Women treated with second‐generation zotarolimus‐eluting resolute stents and everolimus‐eluting xience V stents: insights from the gender‐stratified, randomized, controlled TWENTE trial

J. W. Louwerenburg, M. Stoel, F. H. Man, 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry.

M. Stoel, C. von Birgelen, F. de Man, 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis

H. Suryapranata, A. Finn, L. Mauri, 2013, BMJ.

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2014, The Lancet.

Effect of oversized partial postdilatation on coatings of contemporary durable polymer-based drug-eluting stents: a scanning electron microscopy study.

C. von Birgelen, A. V. van Apeldoorn, Mounir W Z Basalus, 2011, Journal of interventional cardiology.

"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2018, JACC. Cardiovascular interventions.

Recent insights from scanning electron microscopic assessment of durable polymer-coated drug-eluting stents

D. Grijpma, C. Birgelen, M. Z. Basalus, 2012 .

A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2012, Journal of the American College of Cardiology.

Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial.

Maarten J. IJzerman, C. von Birgelen, G. Linssen, 2014, American heart journal.

Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2013, Journal of the American College of Cardiology.

Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).

Maarten J. IJzerman, M. Stoel, C. von Birgelen, 2015, JACC. Cardiovascular interventions.

Clinical outcome of patients with implantation of second‐generation drug‐eluting stents in the right coronary ostium: Insights from 2‐year follow‐up of the TWENTE trial

Maarten J. IJzerman, M. Stoel, C. von Birgelen, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers population.

M. Stoel, C. von Birgelen, G. Linssen, 2012, American heart journal.

Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents.

M. Stoel, C. von Birgelen, G. Linssen, 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Clinical assessment of drug-eluting stents: Twente trial and beyond

K. Tandjung, 2014 .

Incidence of periprocedural myocardial infarction following stent implantation: Comparison between first‐ and second‐generation drug‐eluting stents

M. Stoel, C. von Birgelen, G. Linssen, 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Three‐year clinical outcome after treatment of chronic total occlusions with second‐generation drug‐eluting stents in the TWENTE trial

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Optimizing vessel healing following drug eluting stent implantation with biodegradable polymer DES.

C. Macaya, E. Cerrato, J. Escaned, 2014, Minerva cardioangiologica.

Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.

C. von Birgelen, K. Yadav, C. Doggen, 2016, International journal of cardiology.

CORONARY INTERVENT IONS

J. W. Louwerenburg, M. Stoel, G. Linssen, 2014 .

TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectives

J. W. Louwerenburg, M. Stoel, F. H. Man, 2010, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents 2-Year Follow-Up of the Randomized TWENTE Trial

M. Stoel, G. Linssen, C. Birgelen, 2013 .